Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer

The main treatment modalities for localized prostate cancer are surgery and radiation. Surgery removes the whole prostate gland, whereas with radiation therapy the irradiated prostate remains within the patient's body. Biomarkers specific to the prostate gland should become undetectable after s...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasser, Nicola J., Klein, Jonathan, Agbarya, Abed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Critical Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811126/
https://www.ncbi.nlm.nih.gov/pubmed/33490732
http://dx.doi.org/10.1016/j.adro.2020.10.016
_version_ 1783637437226942464
author Nasser, Nicola J.
Klein, Jonathan
Agbarya, Abed
author_facet Nasser, Nicola J.
Klein, Jonathan
Agbarya, Abed
author_sort Nasser, Nicola J.
collection PubMed
description The main treatment modalities for localized prostate cancer are surgery and radiation. Surgery removes the whole prostate gland, whereas with radiation therapy the irradiated prostate remains within the patient's body. Biomarkers specific to the prostate gland should become undetectable after surgery, but this is not the case when radiation therapy is used, as residual prostate cells may still be metabolically active. Here, we review the role of tumor markers of toxicity and response to radiation therapy in patients with prostate cancer, including prostate specific antigen, human kallikrein 2, osteopontin, prostate cancer associated 3, citrulline, and others.
format Online
Article
Text
id pubmed-7811126
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78111262021-01-22 Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer Nasser, Nicola J. Klein, Jonathan Agbarya, Abed Adv Radiat Oncol Critical Review The main treatment modalities for localized prostate cancer are surgery and radiation. Surgery removes the whole prostate gland, whereas with radiation therapy the irradiated prostate remains within the patient's body. Biomarkers specific to the prostate gland should become undetectable after surgery, but this is not the case when radiation therapy is used, as residual prostate cells may still be metabolically active. Here, we review the role of tumor markers of toxicity and response to radiation therapy in patients with prostate cancer, including prostate specific antigen, human kallikrein 2, osteopontin, prostate cancer associated 3, citrulline, and others. Elsevier 2020-10-27 /pmc/articles/PMC7811126/ /pubmed/33490732 http://dx.doi.org/10.1016/j.adro.2020.10.016 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Critical Review
Nasser, Nicola J.
Klein, Jonathan
Agbarya, Abed
Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer
title Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer
title_full Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer
title_fullStr Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer
title_full_unstemmed Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer
title_short Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer
title_sort markers of toxicity and response to radiation therapy in patients with prostate cancer
topic Critical Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811126/
https://www.ncbi.nlm.nih.gov/pubmed/33490732
http://dx.doi.org/10.1016/j.adro.2020.10.016
work_keys_str_mv AT nassernicolaj markersoftoxicityandresponsetoradiationtherapyinpatientswithprostatecancer
AT kleinjonathan markersoftoxicityandresponsetoradiationtherapyinpatientswithprostatecancer
AT agbaryaabed markersoftoxicityandresponsetoradiationtherapyinpatientswithprostatecancer

Ejemplares similares